BACKGROUND: The hypothesis was that torasemide, due to more predictable pharmacokinetics/pharmacodynamics, induces greater improvements in functional and social limitation than furosemide and reduces the frequency of hospitalisations in primary care patients with chronic heart failure (CHF). PATIENTS AND METHODS: Prospective, randomized, unblinded study in primary care, 237 patients with CHF (NYHA II-IV), all on ACE inhibitors. Randomisation: torasemide (n=122) or furosemide (n=115), treated for 9 months. ENDPOINTS: Clinical efficacy, quality of life, safety, tolerability, hospitalisations. RESULTS:Clinical improvement was observed in both groups, but the trend to improve by at least one NYHA class was significant only in torasemide- (P=0.014), but not in furosemide-treated patients. There were no differences with regard to adverse events and hospitalisation due to CHF. Overall, tolerability (P=0.0001) and improvement in daily restrictions (P=0.0002) were significantly higher, number of mictions at 3, 6 and 12 h after diuretic intake (P<0.001 at all time points) and urgency to urinate (P<0.0001) significantly lower in torasemide- vs. furosemide-treated patients. CONCLUSION: CHF patients treated with torasemide gain a higher benefit in quality of life than furosemide treated patients, due to torasemide's dual effect on both clinical status and social function.
RCT Entities:
BACKGROUND: The hypothesis was that torasemide, due to more predictable pharmacokinetics/pharmacodynamics, induces greater improvements in functional and social limitation than furosemide and reduces the frequency of hospitalisations in primary care patients with chronic heart failure (CHF). PATIENTS AND METHODS: Prospective, randomized, unblinded study in primary care, 237 patients with CHF (NYHA II-IV), all on ACE inhibitors. Randomisation: torasemide (n=122) or furosemide (n=115), treated for 9 months. ENDPOINTS: Clinical efficacy, quality of life, safety, tolerability, hospitalisations. RESULTS: Clinical improvement was observed in both groups, but the trend to improve by at least one NYHA class was significant only in torasemide- (P=0.014), but not in furosemide-treated patients. There were no differences with regard to adverse events and hospitalisation due to CHF. Overall, tolerability (P=0.0001) and improvement in daily restrictions (P=0.0002) were significantly higher, number of mictions at 3, 6 and 12 h after diuretic intake (P<0.001 at all time points) and urgency to urinate (P<0.0001) significantly lower in torasemide- vs. furosemide-treated patients. CONCLUSION:CHFpatients treated with torasemide gain a higher benefit in quality of life than furosemide treated patients, due to torasemide's dual effect on both clinical status and social function.
Authors: Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor Journal: Am Heart J Date: 2015-01-06 Impact factor: 4.749
Authors: Robert J Mentz; Keld Kjeldsen; Gian Paolo Rossi; Adriaan A Voors; John G F Cleland; Stefan D Anker; Mihai Gheorghiade; Mona Fiuzat; Patrick Rossignol; Faiez Zannad; Bertram Pitt; Christopher O'Connor; G Michael Felker Journal: Eur J Heart Fail Date: 2014-03-05 Impact factor: 15.534
Authors: Robert J Mentz; Jonathan Buggey; Mona Fiuzat; Mads K Ersbøll; Phillip J Schulte; Adam D DeVore; Eric L Eisenstein; Kevin J Anstrom; Christopher M OʼConnor; Eric J Velazquez Journal: J Cardiovasc Pharmacol Date: 2015-05 Impact factor: 3.105
Authors: Robert J Mentz; Eric J Velazquez; Marco Metra; Colleen McKendry; Karen Chiswell; Mona Fiuzat; Michael M Givertz; Adriaan A Voors; John R Teerlink; Christopher M O'Connor Journal: Future Cardiol Date: 2015-09-25